Scarica l'app Stockscreener
2.06
5.50%
-0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$2.18
Aprire:
$2.25
Volume 24 ore:
397.61K
Relative Volume:
1.47
Capitalizzazione di mercato:
$52.66M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.8727
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
+8.71%
1M Prestazione:
+8.99%
6M Prestazione:
-11.21%
1 anno Prestazione:
-29.69%
Intervallo 1D:
$2.03
$2.27
Intervallo di 1 settimana:
$1.838
$2.27
Portata 52W:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.06 | 52.66M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics Inc (GANX) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Market Watch: Soleno Therapeutics Inc (SLNO)’s Noteworthy Gain, Closing at 75.02 - DWinneX
Gain Therapeutics Inc [GANX] Records 50-Day SMA of $1.9700 - knoxdaily.com
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 46.30, Up 0.13 - DWinneX
Gain Therapeutics Inc (GANX) Stock: Navigating Drops and Gains - investchronicle.com
Market Watch: ITeos Therapeutics Inc (ITOS)’s Noteworthy Gain, Closing at 7.25 - DWinneX
Gain Therapeutics to Participate at The Citizens Life Sciences Conference - Eagle-Tribune
Gain Therapeutics Inc (GANX) deserves deeper analysis - uspostnews.com
Gain Therapeutics Announces Oral Poster Presentation - marketscreener.com
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics, Inc. Announces Oral Poster Presentation of GT-02287 for Parkinson's Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.84, Down -0.21 - DWinneX
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
EOM Pharmaceuticals (OTCMKTS:IMUC) Stock Price Down 0.8% – Time to Sell? - American Banking and Market News
Market Insights: Denali Therapeutics Inc (DNLI)’s Notable Gain of 4.17, Closing at 15.49 - DWinneX
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.6% – Here’s Why - American Banking and Market News
Gain Therapeutics (NASDAQ:GANX) Trading Up 1.6% – Here’s Why - Defense World
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 41.21, Up 1.75 - DWinneX
Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - uspostnews.com
Gaining Ground: BriaCell Therapeutics Corp (BCTX) Closes Higher at 5.43, Up 1.50 - DWinneX
Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - The Malaysian Reserve
Gaining Ground: Summit Therapeutics Inc (SMMT) Closes Higher at 27.35, Up 8.45 - DWinneX
Daily Market Movement: Mersana Therapeutics Inc (MRSN) Sees a 15.02 Increase, Closing at 0.38 - DWinneX
Can you still get a good price for Applied Therapeutics Inc (APLT) Shares at this point? - uspostnews.com
Daily Progress: Neumora Therapeutics Inc (NMRA) Gain 2.67, Closing at 0.65 - DWinneX
Can you now get a good deal on Enliven Therapeutics Inc’s shares? - uspostnews.com
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.85, Down -1.42 - DWinneX
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week - Yahoo Finance
Viking Therapeutics Stock Pops But Struggles to Hold Gains - MarketBeat
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Yahoo Finance
Can you now get a good deal on Tenaya Therapeutics Inc’s shares? - uspostnews.com
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - Yahoo Finance
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Insider Monkey
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn - Insider Monkey
Gain Therapeutics reports progress in Parkinson’s disease study By Investing.com - Investing.com South Africa
Gain Therapeutics Unveils New Parkinson’s Treatment Data - TipRanks
Gain Therapeutics reports progress in Parkinson's disease study - Investing.com Australia
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update - The Manila Times
Can you now get a good deal on Akero Therapeutics Inc’s shares? - uspostnews.com
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Price Target from Analysts - Defense World
Roth Capital Issues Optimistic Estimate for GANX Earnings - Defense World
Q1 Earnings Forecast for GANX Issued By Roth Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Chardan Capital Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gain Therapeutics Inc Azioni (GANX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):